Carnevale Lab

Research focus

NIH R01 · 2025

Decoding the Cullin-5 complex to engineer therapeutic T cells with durable effector function

Background: T cell therapies represent one of the most promising recent developments in oncology, with impressive responses in certain leukemias and lymphomas resulting in the FDA approval of six CAR-T cell therapies. However, it has become increasingly clear that there are numerous challenges to the successful application of these therapies to a broader spectrum of malignancies. One significant obstacle is the development of T cell dysfunction that can result from chronic tumor antigen stimulation. Preliminary Data: Our genome-wide CRISPR screens in primary human T cells subjected to the pressure of repeated tumor stimulation identified nearly every core subunit of the Cullin-5 E3…

From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.